🇺🇸 FDA
Pipeline program

Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.

CBR-CMR316-3001

Phase 1 other active

Quick answer

Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis. for Idiopathic Pulmonary Fibrosis is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
The George Institute
Indication
Idiopathic Pulmonary Fibrosis
Phase
Phase 1
Modality
other
Status
active

Clinical trials